| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910786 | Lung Cancer | 2015 | 7 Pages |
Abstract
The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yusuke Narita, Yukiko Matsushima, Takeru Shiroiwa, Koji Chiba, Yoichi Nakanishi, Tatsuo Kurokawa, Hisashi Urushihara,